206 related articles for article (PubMed ID: 38013642)
1. Identification of hypoxia-related gene signatures based on multi-omics analysis in lung adenocarcinoma.
Luo Q; Li X; Meng Z; Rong H; Li Y; Zhao G; Zhu H; Cen L; Liao Q
J Cell Mol Med; 2024 Jan; 28(2):e18032. PubMed ID: 38013642
[TBL] [Abstract][Full Text] [Related]
2. Multi-omics immune regulatory mechanisms in lung adenocarcinoma metastasis and survival time.
Liu D; Yao L; Ding X; Zhou H
Comput Biol Med; 2023 Sep; 164():107333. PubMed ID: 37586202
[TBL] [Abstract][Full Text] [Related]
3. Genome-wide analysis of the hypoxia-related DNA methylation-driven genes in lung adenocarcinoma progression.
Li H; Tong L; Tao H; Liu Z
Biosci Rep; 2020 Feb; 40(2):. PubMed ID: 32031203
[TBL] [Abstract][Full Text] [Related]
4. Leveraging diverse cell-death patterns to predict the clinical outcome of immune checkpoint therapy in lung adenocarcinoma: Based on muti-omics analysis and vitro assay.
Liang H; Li Y; Qu Y; Zhang L
Oncol Res; 2023; 32(2):393-407. PubMed ID: 38186574
[TBL] [Abstract][Full Text] [Related]
5. Signatures of Multi-Omics Reveal Distinct Tumor Immune Microenvironment Contributing to Immunotherapy in Lung Adenocarcinoma.
Huang Z; Li B; Guo Y; Wu L; Kou F; Yang L
Front Immunol; 2021; 12():723172. PubMed ID: 34539658
[TBL] [Abstract][Full Text] [Related]
6. Subtype classification based on t cell proliferation-related regulator genes and risk model for predicting outcomes of lung adenocarcinoma.
Yang Q; Zhu W; Gong H
Front Immunol; 2023; 14():1148483. PubMed ID: 37077919
[TBL] [Abstract][Full Text] [Related]
7. Multi-omics analysis unravels the underlying mechanisms of poor prognosis and differential therapeutic responses of solid predominant lung adenocarcinoma.
Li F; Wang S; Wang Y; Lv Z; Jin D; Yi H; Fu L; Zhai S; Xiao T; Mao Y
Front Immunol; 2023; 14():1101649. PubMed ID: 36845145
[TBL] [Abstract][Full Text] [Related]
8. Immunological role and clinical prognostic significance of P2RY6 in lung adenocarcinoma: a multi-omics studies and single-cell sequencing analysis.
Wu H; Dong X
World J Surg Oncol; 2023 Oct; 21(1):341. PubMed ID: 37880703
[TBL] [Abstract][Full Text] [Related]
9. Differences in genetics and microenvironment of lung adenocarcinoma patients with or without TP53 mutation.
Zeng D; Hu Z; Yi Y; Valeria B; Shan G; Chen Z; Zhan C; Lin M; Lin Z; Wang Q
BMC Pulm Med; 2021 Oct; 21(1):316. PubMed ID: 34635074
[TBL] [Abstract][Full Text] [Related]
10. Hypoxia-related gene signature for predicting LUAD patients' prognosis and immune microenvironment.
Chen J; Fu Y; Hu J; He J
Cytokine; 2022 Apr; 152():155820. PubMed ID: 35176657
[TBL] [Abstract][Full Text] [Related]
11. Construction and validation of a prognostic model for lung adenocarcinoma based on endoplasmic reticulum stress-related genes.
Li F; Niu Y; Zhao W; Yan C; Qi Y
Sci Rep; 2022 Nov; 12(1):19857. PubMed ID: 36400857
[TBL] [Abstract][Full Text] [Related]
12. [Construction and Validation of Prognostic Risk Score Model of Autophagy Related Genes in Lung Adenocarcinoma].
Zhou J; Wang X; Li Z; Jiang R
Zhongguo Fei Ai Za Zhi; 2021 Aug; 24(8):557-566. PubMed ID: 34256900
[TBL] [Abstract][Full Text] [Related]
13. Multiomics analysis on DNA methylation and the expression of both messenger RNA and microRNA in lung adenocarcinoma.
Yang Z; Liu B; Lin T; Zhang Y; Zhang L; Wang M
J Cell Physiol; 2019 May; 234(5):7579-7586. PubMed ID: 30370535
[TBL] [Abstract][Full Text] [Related]
14. A novel transcriptomic signature associated with lymphovascular invasion predicts clinical outcomes, tumor microenvironment, and therapeutic response in lung adenocarcinoma.
Huang X; Feng Y; Li Y; Ding H; Huang X; Chen C; Yu Z; Zhang J; Xu X; Ma D; Yu S; Chen C
Int Immunopharmacol; 2024 Jan; 127():111286. PubMed ID: 38064818
[TBL] [Abstract][Full Text] [Related]
15. Development and validation of a MUC16 mutation-associated immune prognostic model for lung adenocarcinoma.
Liu H; Xin T; Duan H; Wang Y; Shao C; Zhu Y; Wang J; He J
Aging (Albany NY); 2023 Jun; 15(12):5650-5661. PubMed ID: 37341998
[TBL] [Abstract][Full Text] [Related]
16. Cancer Stemness-Based Prognostic Immune-Related Gene Signatures in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma.
Li N; Li Y; Zheng P; Zhan X
Front Endocrinol (Lausanne); 2021; 12():755805. PubMed ID: 34745015
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value and immune infiltration of a novel stromal/immune score-related P2RY12 in lung adenocarcinoma microenvironment.
Yu L; Cao S; Li J; Han B; Zhong H; Zhong R
Int Immunopharmacol; 2021 Sep; 98():107734. PubMed ID: 34175738
[TBL] [Abstract][Full Text] [Related]
18. Genome-wide analysis of methylation CpG sites in gene promoters identified four pairs of CpGs-mRNAs associated with lung adenocarcinoma prognosis.
Pan X; Ji P; Deng X; Chen L; Wang W; Li Z
Gene; 2022 Feb; 810():146054. PubMed ID: 34737001
[TBL] [Abstract][Full Text] [Related]
19. Prognosis and immunotherapy significances of a cancer-associated fibroblasts-related gene signature in lung adenocarcinoma.
Luo Y; Zhang S; Xie H; Su Q; He S; Lei Z
Cell Mol Biol (Noisy-le-grand); 2023 Dec; 69(14):51-61. PubMed ID: 38279482
[TBL] [Abstract][Full Text] [Related]
20. Identification and validation of smoking-related genes in lung adenocarcinoma using an in vitro carcinogenesis model and bioinformatics analysis.
Wang J; Chen T; Yu X; OUYang N; Tan L; Jia B; Tong J; Li J
J Transl Med; 2020 Aug; 18(1):313. PubMed ID: 32795291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
